The Inflation Reduction Act creates instability in the Medicare Part D Program.
Not-So-Happy Birthday to the Inflation Reduction Act
The Inflation Reduction Act will ultimately raise drug costs and reduce future cures.
The FTC Wrongly Blames PBMs for High Drug Prices
Putting the customer at the core of your product development ensures relevance and resonance.
New Study Shows PBMs Lower Drug Prices
A new report challenges assertions made during the committee’s recent hearing on the role of pharmacy benefit managers.
The FTC Wrongly Blames PBMs for High Drug Prices
The FTC fails to acknowledge the benefits of pharmacy benefit managers and wrong blames them for high drug prices.
Recognizing and Protecting Medical Invention and Innovation on World IP Day
There is nothing more important to strengthening innovation than protecting and promoting intellectual property in healthcare.
Vermont Governor Takes the Right Approach to Tobacco Harm Reduction
Gov. Scott should be praised for his commonsense approach to legislating tobacco harm reduction products.
Lives Hang in the Balance While the FDA Bureaucracy Churns
The government red tape contributing to the backlog of PMTAs has put consumers at risk with illicit products.
Medicare Advantage Should Not Be Disadvantaged
Taxpayers and beneficiaries should be concerned with the Biden administration’s proposed cuts to Medicare Advantage.
FDA Hurts Patients By Authorizing Florida’s Drug Importation Program
On January 5, 2024, the U.S. FDA authorized Florida’s drug importation program.